T2238C ANP gene variant and risk of recurrent acute coronary syndromes in an Italian cohort of ischemic heart disease patients

Journal of Cardiovascular Medicine

Volumn 17, Issue 8, 2016, Pages 601-607

  Rubattu, Speranza ^a,b   De Giusti, Marco ^b   Farcomeni, Alessio ^c   Abbolito, Sofia ^b   Comito, Filomena ^b   Cangianiello, Sara ^b   Greco, Ettore S ^b   Dito, Eleonora ^b   Pagliaro, Beniamino ^b   Cotugno, Maria ^a   Stanzione, Rosita ^a   Marchitti, Simona ^a   Bianchi, Franca ^a   Di Castro, Sara ^a   Battistoni, Allegra ^b   Burocchi, Simone ^b   Caprinozzi, Massimo ^b   Pierelli, Giorgia ^b   Sciarretta, Sebastiano ^a   Volpe, Massimo ^a,b  

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute coronary syndrome; atrial natriuretic peptide; cardiovascular risk; prognosis; T2238C variant

Indexed keywords

ACETYLSALICYLIC ACID; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGE; ALLELE; ARTICLE; BARE METAL STENT; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ELUTING CORONARY STENT; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; HEART MUSCLE REVASCULARIZATION; HETEROZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; ITALIAN (CITIZEN); MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; RECURRENT ACUTE CORONARY SYNDROME; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK REDUCTION; SCREENING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNSTABLE ANGINA PECTORIS; AGED; ANGINA, UNSTABLE; GENETICS; HEART INFARCTION; ITALY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ACUTE CORONARY SYNDROME; AGED; ALLELES; ANGINA, UNSTABLE; ASPIRIN; ATRIAL NATRIURETIC FACTOR; FEMALE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84913538081     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000195     Document Type: Article

References (30)

1. Rubattu S, Sciarretta S, Valenti V, et al. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 2008; 21:733-741.
2. Rubattu S, Sciarretta S, Marchitti S, et al. NT-proANP/ANP is a determinant of vascular damage in humans. High Blood Press Cardiovasc Prev 2010; 17:117-120.
3. Barbato A, Sciarretta S, Marchitti S, et al. Aminoterminal natriuretic peptides and cardiovascular risk in an Italian male adult cohort. Int J Cardiol 2011; 152:245-246.
4. Lynch AI, Claas SA, Arnett DK. A review of the role of atrial natriuretic peptide gene polymorphisms in hypertension and its sequelae. Curr Hypertens Rep 2009; 11:35-42.
5. Rubattu S, Stanzione R, Di Angelantonio E, et al. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke 2004; 35:814-818.
6. Gruchala M, Ciecwierz D, Wasag B, et al. Association of the ScaI atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease. Am Heart J 2003; 145:125-131.
7. Barbato E, Bartunek J, Mangiacapra F, et al. Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. J Am Coll Cardiol 2012; 59:1763-1770.
8. Ziaee S, Kalayinia S, Boroumand MA, Pourgholi L, Cheraghi S, Anvari MS, Sheikhvatan M. Association between the atrial natriuretic peptide rs5065 gene polymorphism and the presence and severity of coronary artery disease in an Iranian population. Coronary artery disease 2014; 25:242-246.
9. Larifla L, Maimaitiming S, Velayoudom-Cephise FL, et al. Association of 2238T/C polymorphism of the atrial natriuretic peptide gene with coronary artery disease in Afro-Caribbeans with type 2 diabetes. Am J Hypertens 2012; 25:524-527.
10. Ellis KL, Newton-Cheh C, Wang TJ, et al. Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. J Mol Cell Cardiol 2011; 50:695-701.
11. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007; 116:2634-2653.
12. Neal B, MacMahon S. The World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration: prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments. Curr Hypert Rep 1999; 1:346-356.
13. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization. Diabetes Res Clin Pract 1999; 44:21-26.
14. National Cholesterol Education program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
15. Lim H, Liu J, Melzer-Lange M. Comparison of methods for analyzing recurrent events data: application to the emergency department visits of pediatric firearm victims. Accid Anal Prev 2007; 39:290-299.
16. Koren A, Steinberg D, Drory Y, Gerber Y. The Israel study group on first acute myocardial infarction Socioeconomic environment and recurrent coronary events after initial myocardial infarction. Ann Epidemiol 2012; 22:541-546.
17. McGilchrist CA, Aisbett CW. Regression with frailty in survival analysis. Biometrics 1991; 47:461-466.
18. Vanuzzo D, Lo NC, Pilotto L, et al., Gruppo di Ricerca dell'Osservatorio Epidemiologico Cardiovascolare. Cardiovascular epidemiologic observatory 2008-2011: preliminary results. G Ital Cardiol (Rome) 2010; 11 (5 Suppl 3):25S-30S.
19. Palmieri L, Lo Noce C, Vanuzzo D, et al., Gruppo di Ricerca dell'Osservatorio Epidemiologico Cardiovascolare. Cardiovascular epidemiologic observatory: temporal trends of cardiovascular risk factors. G Ital Cardiol (Rome) 2010; 11 (5 Suppl 3):31S-36S.
20. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277:115-121.
21. Parsons RW, Hung J, Hanemaaijer I, et al. Prior calcium channel blockade and short-term survival following acute myocardial infarction. Cardiovasc Drugs Ther 2001; 15:487-492.
22. Allonen J, Nieminen MS, Lokki M, et al. Mortality rate increases steeply with non adherence to statin therapy in patients with acute coronary syndrome. Clin Cardiol 2012; 35:E22-E27.
23. Gordin J, Haider A, Swaminathan RV, et al. Impact of long-term statin therapy on postprocedural myocardial infarction in patients undergoing non emergency percutaneous coronary intervention. Am J Cardiol 2012; 110:1397-1404.
24. Modig K, Andersson T, Drefahl S, Ahlbom A. Age-specific trends in morbidity, mortality and case-fatality from cardiovascular disease, myocardial infarction and stroke in advanced age: evaluation in the Swedish population. Plos One 2013; 8:e64928.
25. Ahmed E, Alhabib KF, El-Menyar A, et al. Age and clinical outcomes in patients presenting with acute coronary syndromes. J Cardiovasc Dis Res 2013; 4:134-139.
26. Ostadal B, Ostadal P. Sex-based differences in cardiac ischemic injury and protection: Therapeutic implications. Br J Pharmacol 2013; 171:541-554.
27. Scarpino S, Marchitti S, Stanzione R, et al. Reactive oxygen speciesmediated effects on vascular remodeling induced by human atrial natriuretic peptide T2238C molecular variant in endothelial cells in vitro. J Hypertens 2009; 27:1804-1813.
28. Sciarretta S, Marchitti S, Bianchi F, et al. C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling. Circ Res 2013; 112:1355-1364.
29. Cannone V, Huntley BK, Olson TM, et al. Atrial natriuretic peptide gene variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up study. Hypertension 2013; 62:860-865.
30. Lynch AI, Boerwinkle E, Davis BR, et al. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA 2008; 299:296-307.